key: cord-1005518-rmn7jpe4
authors: DiMuzio, Jillian M.; Heimbach, Baron C.; Howanski, Raymond J.; Dowling, John P.; Patel, Nirja B.; Henriquez, Noeleya; Nicolescu, Chris; Nath, Mitchell; Polley, Antonio; Bingaman, Jamie L.; Smith, Todd; Harman, Benjamin C.; Robinson, Matthew K.; Morin, Michael J.; Nikitin, Pavel A.
title: Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein
date: 2021-04-24
journal: Vaccine X
DOI: 10.1016/j.jvacx.2021.100098
sha: 65fa09175ee2c90dc1e6bf8231d38fb49680ba18
doc_id: 1005518
cord_uid: rmn7jpe4

Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells against multiple viral proteins. Here, an unbiased interrogation of the anti-viral memory B cell repertoire of convalescent patients has been performed by generating large, stable hybridoma libraries and screening thousands of monoclonal antibodies to identify specific, high-affinity immunoglobulins (Igs) directed at distinct viral components. As expected, a significant number of antibodies were directed at the Spike (S) protein, a majority of which recognized the full-length protein. These full-length Spike specific antibodies included a group of somatically hypermutated IgMs. Further, all but one of the six COVID-19 convalescent patients produced class-switched antibodies to a soluble form of the receptor-binding domain (RBD) of S protein. Functional properties of anti-Spike antibodies were confirmed in a pseudovirus neutralization assay. Importantly, more than half of all of the antibodies generated were directed at non-S viral proteins, including structural nucleocapsid (N) and membrane (M) proteins, as well as auxiliary open reading frame-encoded (ORF) proteins. The antibodies were generally characterized as having variable levels of somatic hypermutations (SHM) in all Ig classes and sub-types, and a diversity of VL and VH gene usage. These findings demonstrated that an unbiased, function-based approach towards interrogating the COVID-19 patient memory B cell response may have distinct advantages relative to genomics-based approaches when identifying highly effective anti-viral antibodies directed at SARS-CoV-2.

As the one-year mark approaches since its emergence in Wuhan, China in late 2019 [1] , the prolonged spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has resulted in one of the most devastating global health challenges of the last century [2] [3] [4] . With greater than 45 million confirmed cases and nearly 1.2 million deaths world-wide (WHO, as of November 2020 [5] ), the virus continues to pose an extraordinary challenge to the scientific community, consequently becoming an unprecedented socio-economic disaster and burdening healthcare systems around the world. Infection with SARS-CoV-2 results in a myriad pathologies [6] collectively referred to as COVID-19 [3] . While a majority of individuals who become infected with the virus are capable of generating a productive anti-viral response, for many their anti-viral humoral response will not be sufficient to shield them from a potentially deadly infection. Therefore, as the global community braces for the next spike in infection and mortality rates, the urgency to develop effective therapeutics recapitulating the productive anti-viral response to combat the swelling health crisis has never been greater.

SARS-CoV-2 genomic RNA contains a large viral replicase gene, genes encoding nonstructural proteins at its 5' end, and a region encoding four major structural and multiple accessory proteins at the 3' end. Structural proteins include Spike or Surface glycoprotein (S), Membrane protein (M), Envelope protein (E) and Nucleocapsid protein (N) [7] . The membrane surface glycoprotein S consists of two subunits, S1 and S2, that mediate viral binding to the host receptor ACE2 and fusion with the host cell membrane, respectively.

The S1 subunit contains the receptor binding domain (RBD) that directly interacts with ACE2 and is a target of multiple neutralizing antibodies currently in clinical trials [8, 9] .

Genetic analyses of immune effector cells from convalescent patients who had effectively cleared the SARS-CoV-2 virus revealed that these individuals often had robust T and B cell responses to multiple other viral antigens beyond S protein [10] [11] [12] [13] [14] , suggesting that the recognition of multiple antigens beyond the S protein may be important for viral clearance and the efficient resolution of infection. Included among the targets of the adaptive immune response were N and M proteins, as well as proteins encoded by the viral open reading frame (ORF). As such, a multi-targeted mixture of high-affinity anti-SARS-CoV-2-specific antibodies, more reflective of the broad humoral response seen in high-titer, mild to moderate COVID-19 convalescent patients, may be a more effective therapeutic strategy than using S-specific antibodies alone.

This report describes studies to elucidate the memory B cell antibody response in convalescent patients, using a method that enables the generation of large, stable hybridoma libraries from primary human B cells. This approach was previously used to identify a panel of monoclonal antibodies from convalescent patients infected with natural polio virus (PV), oral PV-vaccinated and inactivated PV-boosted healthy subjects [15] [16] [17] , and, most recently, an anti-amyloid antibody with the anti-biofilm activity [18] from a hybridoma library generated with memory B cells from an Alzheimer's Disease patient [19] . In the current report, eleven hybridoma libraries were generated from the memory B cells of six COVID-19 patients. These libraries were comprised of more than 150 distinct monoclonal antibodies that were selected on the basis of their binding to multiple SARS-CoV-2 proteins in both cell-based and target-based screens. Characterization of these antibodies revealed broad responses to diverse viral antigens. Fewer than half of the antibodies were directed at S protein, while the remainder were directed at other viral proteins including N and ORF-encoded proteins. Even though the antibodies were directed at highly diverse SARS-CoV-2 antigens, they were generally characterized as having variable levels of somatic hypermutation (SHM) and a diversity of V L and V H gene usage. Functional properties of anti-Spike antibodies were successfully confirmed in a pseudovirus neutralization assay. These results indicate that an unbiased interrogation of COVID-19 patient B cell repertoires is an effective approach to identifying specific antiviral antibodies and antibody mixtures with the desired binding and functional properties.

Antibodies identified and characterized in this manner could be recombinantly produced to yield therapeutic or prophylactic products to address the COVID-19 pandemic. The rapidity with which antibodies from convalescent patients can be identified and characterized suggests that this platform could be a useful component of a rapid response to future pandemics.

We examined the overall spectrum of the productive antibody response to SARS-CoV-2 using an automated, high-throughput hybridoma library generation and screening platform [15] after isolating memory B cells acquired from blood samples of COVID-19 convalescent patients who demonstrated a high (2880) antibody titer to N and/or S proteins. More than 17,000 hybridomas were generated from the memory B cells of six patients (Table 1) , and the naturally occurring human antibodies (IgM, IgG, and IgA isotypes) secreted by those hybridomas were screened for reactivity against a panel of SARS-CoV-2 proteins. Antibody screening assays were developed for three structural proteins (S, N, M) and a panel of accessory ORF proteins of SARS-CoV-2 ( Table 2 ). The screening assays included a rapid and sensitive homogeneous time resolved fluorescence (hTRF) assay that used soluble recombinant viral proteins (Figure 1) , as well as a selective, cell-based flow cytometry assay that allowed probing of antibodies to transiently transfected viral antigens expressed within the context of human cells ( Figure   2 ). Commercially available antibodies specific for SARS-CoV-2 proteins demonstrated selective and saturable binding in both assays. The dynamic ranges varied among the specific targets and between assays ( Figure 1 and Figure 2 ) within a 10 pM-100 nM window. Viral protein expression in the cell-based assay was additionally confirmed by Western blot. For cell-based assays, using commercially available controls, the localization of the C-terminus truncated Spike protein (SΔ19aa) was confirmed to be on the surface of the transfected cells, while the localization for Nucleocapsid, Membrane, ORF3a, ORF6, ORF7a, ORF8, and ORF10 proteins was predominantly intracellular. 

Consistent with previous reports [12, 14] , S protein was identified as the major antigen for antibody responses in these patients. As shown in Figure 3A , S represented the single most frequently identified target: 76 (44%) of the mono-specific antibodies bound selectively to S protein. As expected, the epitopes for anti-Spike antibodies were distributed across the RBD, non-RBD S1, and non-S1 regions of the Spike protein ( Figure   3B ). However, consistent with the hypothesis that patients would be mounting antibody responses to a broad range of SARS-CoV-2 proteins, more than half (56%) of identified antibodies bound to non-Spike viral antigens ( Figure 3 ). ORF8 -(28 antibodies, 17%) and

N -(23 antibodies, 14%) specific antibodies represented the second and third mostfrequently identified targets, respectively. Of note, the antibodies identified in the hTRF assay were biased toward the IgG class (>80%) ( Figure 4A ). This bias was likely due to lack of sensitivity in the assay for either IgA or IgM, as demonstrated in the control antibody titrations shown in Figure 1 . While IgG was still the predominant isotype (~50%)

in the cell-based screening, IgA (~20%) and IgM (~30%) antibodies were also wellrepresented ( Figure 4B ). Further, these isotypes were also spread across the landscape of antigens being evaluated ( Figure 4C ). and Ab#26, potently neutralized pseudovirus infection with EC50 <500 ng/mL (Table 3) .

Indeed, a full dose response of purified antibodies confirmed strong neutralizing activity of both antibodies ( Figure 7A ). In addition to the WT (Wuhan) reference strain, various mutations in the Spike protein of SARS-CoV-2 are prevalent throughout the population, with the D614G variant being the dominant strain at the moment of writing of this manuscript [29] . Thus, identified neutralizing antibodies were tested against and neutralized the D614G S pseudovirus with comparable EC 50 values ( Figure 7B ). To further enhance neutralizing activity, combinatorial studies looked for any additive effects seen with the addition of anti-Spike antibodies to Ab#3. Ultimately, Ab#1 at various doses was able to enhance neutralizing activity above that of Ab#3 alone ( Figure 7C, D) . [20, 21] and further mutations may ultimately limit the effectiveness of therapies directed at this single protein [22] . The majority of anti-S antibodies, as expected, recognized a full-length S protein (Table   3 ). Further, all but one of the six COVID-19 convalescent patients produced antibodies to a soluble receptor-binding domain of S protein (RBD). Of note, while most of the RBDand S1-specific antibodies were less mutated than those specific to the full-length S protein, we identified several highly mutated RBD-specific outliers. Lower rate of SHM in 

Blood samples were collected from human donors, the samples were deidentified and the B cells were isolated from those deidentified blood samples. Immunome did not seek IRB approval of a "research project" because analysis of biospecimens that are deidentified, coded or anonymized and are not readily identifiable are not subject to human subject regulations (as such, no IRB approval was required to be obtained by Immunome). Immunome also used a commercial vendor, BioIVT, to collect additional blood samples. Given the scope of BioIVT's business and services for its customers,

BioIVT has a standing IRB approval from WCG IRB in place for their donor center collection efforts.

Blood samples were drawn from six convalescing COVID-19 patient volunteers deemed eligible for donating convalescent plasma as set forth in the US FDA's Recommendations [23] . Patients displayed no PCR-detectable viremia and maximal IgG (2880) titer of classswitched, virus-specific antibodies.

Hybridomas were generated following protocols for isolating and expanding primary Bcells as well as electrofusion methods described in U.S. patents [24, 25] . Hybridomas stably expressing human mAbs were generated by electrofusion of expanded B-cells to the B5-6T myeloma cell line, which expresses an ectopic human telomerase gene that stabilizes human chromosomes in the hybrid cells created. Fused hybridomas were plated into 96-well plates in growth medium with HAT selection of stable hybridomas for 7 days. After 7 days, growth media were switched to media with HT for stable selected hybridoma growth. Hybridomas were cultured in a 37°C incubator for 14-21 days during which time they were imaged for monoclonality and monitored for isotype-and sub-classspecific Ig secretion. Supernatants from monoclonal wells expressing measurable levels of Ig were cherry-picked and submitted for target-based screening. fragments of the constant regions were sequenced to identify the isotype of the antibody and compared to the experimentally identified isotype of hybridoma supernatants. The resulting isotype of the heavy or light chain was assigned based on two or more positive readings from experimental (ex. ELISA and FACS) assays and sequencing.

Spike-expressing pseudovirus was generated with System Bioscience's pPACK-SPIKE 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Progress report on the coronavirus pandemic

Emerging Pandemic Diseases: How We Got to COVID-19

COVID-19 outbreak: Migration, effects on society, global environment and prevention

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard

Severe Covid-19

An overview of their replication and pathogenesis. Coronaviruses: Methods and Protocols

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. 2020 [cited 5

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. Res SquareResearch Sq

Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains

Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes

Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression

Salmonella Typhimurium biofilm disruption by a human antibody that binds a pan-amyloid epitope on curli

A human monoclonal IgG that binds Aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

The coronavirus is mutating -does it matter?

Guidance for Industry: FDA's Recommendations for Investigational COVID-19 Conavalescent Plasma. FDA; 2020

HTRF: A technology tailored for drug discovery -A review of theoretical aspects and recent applications

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS

Spike Protein for Neutralization Assays

Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection

Spike mutation D614G alters SARS-CoV-2 fitness